Posted by Michael Wonder on 22 Dec 2021
FDA approves Otezla (apremilast) for the treatment of adult patients with plaque psoriasis, regardless of severity level
20 December 2021 - Otezla is the first and only oral therapy approved in adult patients with plaque psoriasis across all severities, including mild, moderate and severe.
Amgen today announced that the U.S. FDA has approved Otezla (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
